What is Annoroad?
Founded in 2012 and headquartered in Beijing, Annoroad Gene Technology has emerged as a premier enterprise within the Chinese genomics sector. The company operates as a comprehensive service provider, specializing in the application of next-generation genomics to human health and life science research. Annoroad is recognized for its end-to-end industry presence, spanning from the development of high-throughput sequencing instruments and reagents to the provision of sophisticated medical testing and genomic big data services. Its portfolio includes the CFDA-approved NextSeq 550AR sequencer and the SolarGenomics cloud platform, both of which are integral to its mission of driving innovation in precision medicine. With numerous designations as a national high-tech enterprise and a leader in the G20 Biopharmaceutical Industry Program, Annoroad maintains a robust competitive advantage through its proprietary technology and high-performance computing capabilities.
How much funding has Annoroad raised?
Annoroad has raised a total of $100M across 1 funding round:
Series C
$100M
Series C (2017): $100M with participation from SAIF Partners, SBCVC, ShenZhen GTJA Investment Group, and Ping An Ventures
Key Investors in Annoroad
SAIF Partners
SAIF Partners is a prominent private equity firm that specializes in providing growth capital to companies in China or those with significant operations in the region, focusing on sectors including healthcare and TMT.
SBCVC
SBCVC is a leading venture capital and private equity firm that manages both USD and RMB funds, with a specific investment focus on high-tech, high-growth companies in the healthcare and advanced manufacturing sectors.
ShenZhen GTJA Investment Group
Shenzhen GTJA Investment Group is a specialized investment firm focused on the healthcare industry, with particular expertise in pharmaceuticals, medical apparatus, and medical services.
What's next for Annoroad?
With the successful closure of this major strategic investment, Annoroad is poised to enter a new phase of operational expansion and technological refinement. The company is expected to prioritize the scaling of its SolarGenomics platform and the broader deployment of its high-throughput sequencing systems across clinical settings. By focusing on the integration of Bio-IT industrial services, Annoroad aims to deepen its penetration into the precision medicine market, potentially expanding its footprint in international research collaborations. The strategic focus will likely remain on enhancing its bioinformatics capabilities and maintaining its status as a top-tier medical genomics center, ensuring that its product ecosystem continues to meet the rigorous demands of modern healthcare and life science research.
See full Annoroad company page
